These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 24920071

  • 21. Assessment of Life Quality Index and Treatment Efficacy in Psoriasis Vulgaris Patients Receiving Biologic Therapies in a Turkish Population.
    Gundogdu M, Kundakci N, Erdem C.
    Skinmed; 2020; 18(2):84-90. PubMed ID: 32501790
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
    Blauvelt A, Papp KA, Griffiths CEM, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M.
    Am J Clin Dermatol; 2017 Apr; 18(2):273-280. PubMed ID: 28074446
    [Abstract] [Full Text] [Related]

  • 23. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R.
    J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
    [Abstract] [Full Text] [Related]

  • 24. Patient Adherence to Biologic Agents in Psoriasis.
    Hsu DY, Gniadecki R.
    Dermatology; 2016 Apr; 232(3):326-33. PubMed ID: 27093295
    [Abstract] [Full Text] [Related]

  • 25. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
    Phan C, Beauchet A, Burztejn AC, Severino-Freire M, Barbarot S, Girard C, Lasek A, Reguiai Z, Hadj-Rabia S, Abasq C, Brenaut E, Droitcourt C, Perrussel M, Mallet S, Phan A, Lacour JP, Khemis A, Bourrat E, Chaby G, Deborde R, Plantin P, Maruani A, Piram M, Maccari F, Fougerousse AC, Kupfer-Bessaguet I, Balguérie X, Barthelemy H, Martin L, Quiles-Tsimaratos N, Mery-Brossard L, Pallure V, Lons-Danic D, Bouilly-Auvray D, Beylot-Barry M, Puzenat E, Aubin F, Mahé E, Groupe de Recherche de la Société Française de Dermatologie Pédiatrique, Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie.
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
    [Abstract] [Full Text] [Related]

  • 26. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
    Garber C, Creighton-Smith M, Sorensen EP, Dumont N, Gottlieb AB.
    J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
    [Abstract] [Full Text] [Related]

  • 27. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M, Nakamura M, Zhu TH, Farahnik B, Koo J, Bhutani T.
    J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
    [Abstract] [Full Text] [Related]

  • 28. Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52 weeks observation.
    Di Lernia V, Bianchi L, Guerriero C, Stingeni L, Gisondi P, Filoni A, Guarneri C, Belloni Fortina A, Lasagni C, Simonetti O, Neri I, Zangrilli A, Moretta G, Hansel K, Casanova DM, Girolomoni G, Cannavò SP, Bonamonte D.
    Dermatol Ther; 2019 Nov; 32(6):e13091. PubMed ID: 31579972
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study.
    Papp K, Ho V, Teixeira HD, Guerette B, Chen K, Lynde C.
    J Eur Acad Dermatol Venereol; 2012 Aug; 26(8):1007-13. PubMed ID: 22023702
    [Abstract] [Full Text] [Related]

  • 30. Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: a retrospective investigation of 146 psoriasis patients.
    Hoffmann JH, Knoop C, Enk AH, Hadaschik EN.
    J Dermatol Sci; 2014 Dec; 76(3):180-5. PubMed ID: 25306295
    [Abstract] [Full Text] [Related]

  • 31. Long-Term Efficacy of Etanercept for Plaque-Type Psoriasis and Estimated Cost in Daily Clinical Practice.
    María Fernández-Torres R, Paradela S, Fonseca E.
    Value Health; 2015 Dec; 18(8):1158-61. PubMed ID: 26686803
    [Abstract] [Full Text] [Related]

  • 32. Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort.
    Zweegers J, Roosenboom B, van de Kerkhof PC, van den Reek JM, Otero ME, Atalay S, Kuijpers AL, Koetsier MI, Arnold WP, Berends MA, Weppner-Parren L, Bijen M, Njoo MD, Mommers JM, van Lümig PP, Driessen RJ, Kievit W, de Jong EM.
    Br J Dermatol; 2017 Mar; 176(3):786-793. PubMed ID: 27454758
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
    Papp K, Thaçi D, Marcoux D, Weibel L, Philipp S, Ghislain PD, Landells I, Hoeger P, Kotkin C, Unnebrink K, Seyger M, Williams D.
    Lancet; 2017 Jul 01; 390(10089):40-49. PubMed ID: 28478975
    [Abstract] [Full Text] [Related]

  • 34. [Clinical experience with etanercept in the treatment of psoriasis].
    Martín B, Sánchez-Carazo JL, Pérez-Ferriols A, Laguna C, Oliver V, Alegre V.
    Actas Dermosifiliogr; 2008 Sep 01; 99(7):540-5. PubMed ID: 18682167
    [Abstract] [Full Text] [Related]

  • 35. Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab.
    Bissonnette R, Maari C, Barber K, Lynde CW, Vender R.
    J Eur Acad Dermatol Venereol; 2015 Aug 01; 29(8):1576-81. PubMed ID: 25600828
    [Abstract] [Full Text] [Related]

  • 36. Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: A case report and a review of the previous reports on biologic treatments for psoriasis patients with hemodialysis for renal failure.
    Kusakari Y, Yamasaki K, Takahashi T, Tsuchiyama K, Shimada-Omori R, Nasu-Tamabuchi M, Aiba S.
    J Dermatol; 2015 Jul 01; 42(7):727-30. PubMed ID: 25916786
    [Abstract] [Full Text] [Related]

  • 37. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
    Takahashi N, Noda S, Taniguchi T, Adachi M.
    Int J Dermatol; 2015 Oct 01; 54(10):1194-8. PubMed ID: 26016819
    [Abstract] [Full Text] [Related]

  • 38. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
    Gottlieb AB, Lacour JP, Korman N, Wilhelm S, Dutronc Y, Schacht A, Erickson J, Zhang L, Mallbris L, Gerdes S.
    J Eur Acad Dermatol Venereol; 2017 Apr 01; 31(4):679-685. PubMed ID: 27696577
    [Abstract] [Full Text] [Related]

  • 39. Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials.
    Papp KA, Armstrong AW, Reich K, Karunaratne M, Valdecantos W.
    Am J Clin Dermatol; 2016 Feb 01; 17(1):79-86. PubMed ID: 26547918
    [Abstract] [Full Text] [Related]

  • 40. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches.
    Blauvelt A, Lacour JP, Fowler JF, Weinberg JM, Gospodinov D, Schuck E, Jauch-Lembach J, Balfour A, Leonardi CL.
    Br J Dermatol; 2018 Sep 01; 179(3):623-631. PubMed ID: 29917226
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.